STOCK TITAN

Colgate-Palmolive (NYSE: CL) CEO exercises options and sells 322,042 shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Colgate-Palmolive Chairman, President & CEO Noel R. Wallace exercised stock options covering 322,042 shares of common stock at an exercise price of $72.2900 per share on August 4–5, 2026, then sold an equal number of shares at weighted average prices of $91.9179 and $92.5215, with a portion of the sale proceeds delivered to the issuer to pay the option exercise price and related tax withholding.

Reported indirect holdings include 54,868 shares held by the issuer's 401(k) plan trustee, 52,000 shares held by a spouse trust, and 335 shares held by another trust.

Positive

  • None.

Negative

  • None.
Insider Wallace Noel R.
Role Chairman, President & CEO
Sold 322,042 shs ($29.70M)
Approx. gross sale proceeds $29.70M
Approx. exercise cost $23.28M
Approx. pre-tax spread $6.42M
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1, F5 161,021 $0.00 $0.00
Exercise Common Stock F1 161,021 $72.29 $11.64M
Sale Common Stock F2, F4 161,021 $92.5215 $14.90M
Exercise Stock Option (Right to Buy) F1, F5 161,021 $0.00 $0.00
Exercise Common Stock F1 161,021 $72.29 $11.64M
Sale Common Stock F2, F3 161,021 $91.9179 $14.80M
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 362,231 shares (Direct); Common Stock — 54,868 shares (Indirect, By Issuer's 401(k) Plan Trustee); Common Stock — 52,000 shares (Indirect, By Spouse Trust); Common Stock — 335 shares (Indirect, By Trust)
Footnotes (5)
  1. F1. Exercise of stock options awarded under the issuer's incentive compensation plan.
  2. F2. Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding.
  3. F3. Weighted average price, as these shares were sold in multiple transactions at prices ranging from $91.50 to $92.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4. Weighted average price, as these shares were sold in multiple transactions at prices ranging from $92.00 to $92.93, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5. Option became exercisable in one-third increments beginning on the first anniversary of the September 12, 2019 grant date.
Options exercised 322,042 shares Total underlying common shares from derivative exercises on August 4–5, 2026
Shares sold 322,042 shares Common shares sold on August 4–5, 2026 in open-market transactions
Option exercise price $72.2900 per share Exercise price of stock options granted September 12, 2019
August 4, 2026 sale price $91.9179 per share Weighted average sale price for 161,021 shares sold August 4, 2026
August 5, 2026 sale price $92.5215 per share Weighted average sale price for 161,021 shares sold August 5, 2026
Indirect 401(k) holdings 54,868 shares Indirect common stock holdings by issuer's 401(k) plan trustee as of August 4, 2026
Indirect spouse trust holdings 52,000 shares Indirect common stock holdings by spouse trust as of August 4, 2026
Indirect trust holdings 335 shares Indirect common stock holdings by another trust as of August 4, 2026
Stock Option (Right to Buy) financial
"Security title listed as Stock Option (Right to Buy) for derivative entries"
incentive compensation plan financial
"Footnote notes options were awarded under the issuer's incentive compensation plan"
An incentive compensation plan is a formal program that rewards employees and executives with bonuses, stock, or other payments tied to specific performance goals—such as revenue, profit, productivity, or long‑term share price. Investors watch these plans because they shape how leaders make decisions and take risks; like paying a coach by wins rather than effort, well‑designed plans can drive sustainable growth while poor designs can encourage short‑term behaviors that harm shareholder value.
weighted average price financial
"Footnotes F3 and F4 describe a weighted average price for multiple sales"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
tax withholding financial
"Footnote F2 says proceeds covered the exercise price and related tax withholding"
Tax withholding is the practice of taking a portion of a payment—such as wages, dividends, or sale proceeds—before it reaches the recipient and sending that portion to the tax authority as an advance on the recipient’s eventual tax bill. For investors it matters because withholding reduces immediate cash received and affects after‑tax returns, estimated tax payments, and whether you may owe more or receive a refund when taxes are finally calculated, like having a small automatic savings set aside for your tax bill.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transactions did Colgate-Palmolive (CL) CEO Noel R. Wallace report for August 4–5, 2026?

Noel R. Wallace reported exercising 322,042 stock options at $72.2900 per share and selling an equal number of Colgate-Palmolive common shares at weighted average prices of $91.9179 and $92.5215 over August 4–5, 2026.

How many Colgate-Palmolive (CL) stock options did Noel R. Wallace exercise and at what exercise price?

He exercised options for 322,042 underlying common shares at an exercise price of $72.2900 per share. The options were awarded under Colgate-Palmolive’s incentive compensation plan and became exercisable in one-third increments starting one year after the September 12, 2019 grant date.

At what prices did Noel R. Wallace sell Colgate-Palmolive (CL) shares on August 4–5, 2026?

He sold 161,021 shares at a weighted average price of $91.9179 on August 4, 2026, and another 161,021 shares at a weighted average price of $92.5215 on August 5, 2026, in multiple market transactions within specified price ranges.

How were the proceeds from Noel R. Wallace’s Colgate-Palmolive (CL) stock sales used?

Footnotes state that a portion of the sale proceeds was delivered to Colgate-Palmolive to pay the exercise price of the stock options and the related tax withholding, meaning not all cash from the sales represented net proceeds to Wallace.

What indirect Colgate-Palmolive (CL) shareholdings are reported for Noel R. Wallace?

Indirectly reported holdings include 54,868 shares of common stock held by the issuer’s 401(k) plan trustee, 52,000 shares held by a spouse trust, and 335 shares held by another trust, all as of August 4, 2026.

Were Noel R. Wallace’s Colgate-Palmolive (CL) trades reported as made under a Rule 10b5-1 trading plan?

The report’s Rule 10b5-1 checkbox is not marked as an affirmative trading plan, and the footnotes do not describe the transactions as made pursuant to a Rule 10b5-1 or other pre-arranged trading plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wallace Noel R.

(Last)(First)(Middle)
C/O COLGATE-PALMOLIVE COMPANY
300 PARK AVENUE

(Street)
NEW YORK NEW YORK 10022

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
COLGATE PALMOLIVE CO [ CL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman, President & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/04/2026M(1)161,021A$72.29523,252D
Common Stock08/04/2026S(2)161,021D$91.9179(3)362,231D
Common Stock08/05/2026M(1)161,021A$72.29523,252D
Common Stock08/05/2026S(2)161,021D$92.5215(4)362,231D
Common Stock54,868IBy Issuer's 401(k) Plan Trustee
Common Stock52,000IBy Spouse Trust
Common Stock335IBy Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$72.2908/04/2026M(1)161,021 (5)09/12/2027Common Stock161,021$0.0000161,021D
Stock Option (Right to Buy)$72.2908/05/2026M(1)161,021 (5)09/12/2027Common Stock161,021$0.00000.0000D
Explanation of Responses:
1. Exercise of stock options awarded under the issuer's incentive compensation plan.
2. Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding.
3. Weighted average price, as these shares were sold in multiple transactions at prices ranging from $91.50 to $92.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. Weighted average price, as these shares were sold in multiple transactions at prices ranging from $92.00 to $92.93, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. Option became exercisable in one-third increments beginning on the first anniversary of the September 12, 2019 grant date.
/s/ Kristine Hutchinson, Attorney-in-Fact08/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)